Amylyx Pharmaceuticals Inc. (AMLX)
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.35B
- EPS (TTM)
- -$1.43
- Dividend yield
- None
- 52-week range
- 10.83 – 41.14
- Day range
- 25.52 – 26.40
- Volume / Avg
- 1.14M / 1.53M
- Beta
- —
- Shares outstanding
- 128.56M
52-week range
AMLX stock today
Amylyx Pharmaceuticals (AMLX) closed at $26.02 on Nov 20, down 0.69% (-$0.18), versus the S&P 500's 3.70% decline. At this level, AMLX sits in the middle of its 52-week range of $10.83 to $41.14: 36.8% below the high, set on Aug 21, 2026 and 140.3% above the low. AMLX is up 115.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 77.4%.
Amylyx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Amylyx Pharmaceuticals
Company profileAmylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joshua B. Cohen
- Headquarters
- Cambridge, MA
- Employees
- 136
- IPO year
- 2022
- Website
- amylyx.com
Financial highlights
Full financialsIn fiscal 2025, Amylyx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Amylyx Pharmaceuticals reported a net loss of $144.7 million, compared with a loss of $301.7 million a year earlier. Diluted earnings per share came in at -$1.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.37M | $380.79M | $22.23M | $285.00K |
| Growth | -100.00% | -77.06% | +1612.94% | +7700.00% | — |
| Net income | $-144.74M | $-301.74M | $49.27M | $-198.38M | $-87.93M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$43.00+65.26%
- Strong buy 0
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.38 vs $-0.38
- Surprise
- 0.00%
AMLX news
All AMLX news- Amylyx's Avexitide Cuts Low Blood Sugar Events By 55% In Phase 3 Trial; FDA Filing Due Year-EndNasdaqAMLX, BRK.A
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsNasdaqAMLX, LEN.B
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Amylyx Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026Business Wire
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearNasdaqVRTX, AMLX, BBIO, PRAX
Amylyx Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs AMLX |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs AMLX |
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs AMLX |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs AMLX |
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs AMLX |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs AMLX |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs AMLX |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs AMLX |
Indexes, lists and sector
Amylyx Pharmaceuticals stock FAQ
What is Amylyx Pharmaceuticals's stock price today?
AMLX last traded at $26.02 as of Nov 20, 4:00 PM EST, down 0.69% on the day. Prices are delayed at least 15 minutes.
Who is Amylyx Pharmaceuticals's CEO?
Mr. Joshua B. Cohen is the chief executive officer of Amylyx Pharmaceuticals Inc., which has about 136 employees.
What is the AMLX 52-week high?
The 52-week high for AMLX is $41.14 and the 52-week low is $10.83. The stock is currently 36.8% below its high.